natgillin/translations-raw huggingface dataset:
Plasma concentrations of tipranavir can be reduced by concomitant use of the herbal preparation St John's wort (Hypericum perforatum). 
Koncentracije tipranavira u plazmi mogu se smanjiti uz istodobnu primjenu pripravka gospine trave (Hypericum perforatum) zbog indukcije metabolizirajućih enzima.
Due to their metabolic profile and inherent risk of inducing torsades de pointes, administration of halofantrine and lumefantrine with Aptivus, co-administered with low dose ritonavir, is not recommended (see section 4.4). 
Zbog njihovog metaboličkog profila i inherentnog rizika od indukcije torsades de pointes, ne preporučuje se primjena halofantrina i lumefantrina s Aptivusom, s niskom dozom ritonavira (vidjeti dio 4.4).
Your child must not take products containing St John's wort (a herbal remedy for depression). 
Vaše dijete ne smije uzimati proizvode koji sadrže gospinu travu (biljni lijek protiv depresije), jer ona može spriječiti ispravno djelovanje Aptivusa.
Based on theoretical considerations, colchicine concentrations may increase upon co-administration with tipranavir and low dose ritonavir, due to tipranavir/ritonavir CYP3A and P-gp inhibition. 
Temeljem teoretskih razmatranja, koncentracije kolhicina mogu se povećati nakon istodobne primjene s tipranavirom i niskom dozom tipranavira, zbog inhibicije CYP3A i P-gp tipranavirom/ritonavirom.
Also, appropriate dose adjustments for children under 12 years cannot be achieved with Aptivus capsules. 
Također se ne mogu provoditi prilagodbe doziranja Aptivus kapsula za djecu ispod 12 godina starosti.
If you have: 
- emtricitabin:
At least one primary protease gene mutation from among 30N, 46I, 46L, 48V, 50V, 82A, 82F, 82L, 82T, 84V or 90M had to be present at baseline, with not more than two mutations on codons 33, 82, 84 or 90. 
Morala je biti prisutna najmanje jedna od primarnih mutacija gena za proteazu: 30N, 46I, 46L, 48V, 50V, 82A, 82F, 82L, 82T, 84V ili 90M, s ne više od dvije mutacije u kodonima 33, 82, 84, ili 90.
S-methadone Cmax ↓ 62% S-methadone AUC ↓ 63% 
S-metadon Cmax ↓ 62% S-metadon AUC ↓ 63%
Compared to the oral solution, tipranavir exposure is lower when administering the same dose as capsules. 
U usporedbi s oralnom otopinom, izlaganje tipranaviru je manje prilikom primjene jednake doze u obliku kapsula.
25-O-desacetylrifabutin Cmax ↑ 3.2 fold 
25-O-dezacetilrifabutin Cmax ↑ 3,2 puta
500 mg Tipranavir co-administered with low dose ritonavir (200 mg; twice daily) was associated with a 29-fold increase in the geometric mean morning steady-state trough plasma concentrations compared to tipranavir 500 mg twice daily without ritonavir. 
500 mg tipranavira s niskom dozom ritonavira (200 mg; dvaput dnevno) daje 29 puta višu geometrijsku srednju vrijednost jutarnje najniže koncentracije tipranavira na kraju doznog intervala u stanju dinamičke ravnoteže nego 500 mg tipranavira dva puta dnevno bez ritonavira.
If patients did not receive tipranavir with ritonavir with new enfuvirtide, diminished treatment responses at week 48 were observed, relative to new enfuvirtide use (see Table below). 
Ako „novi“ enfuvirtid nije uveden, terapijski odgovor u 48. tjednu bio je slabiji nego uz primjenu „novog“ enfuvirtida (vidjeti tablicu u nastavku).
- 500 mg (two 250 mg capsules) Aptivus together with - 200 mg (two 100 mg capsules) ritonavir twice per day with food. 
Preporučena doza za odrasle ili adolescente dobi od 12 i više godina je: - 500 mg (dvije kapsule od 250 mg) Aptivusa zajedno s - 200 mg (dvije kapsule od 100 mg) ritonavira dvaput dnevno s hranom.
Tell your doctor if you receive medicines such as blood-thinning agents, or if you are taking vitamin E. Your doctor may wish to consider certain precautionary measures in such circumstances. 
Obavijestite liječnika ako uzimate lijekove kao što su lijekovi za razrjeđivanje krvi, ili ako uzimate vitamin E.
Variable 
Varijabla
ALAT increased 
Povišeni ALT
Pink, oblong soft gelatin capsules imprinted with “TPV 250” in black. 
Ružičasta, duguljasta meka kapsula od želatine s, crnom bojom, utisnutim „TPV 250“.
MARKETING AUTHORISATION NUMBER(S) EU/1/05/315/001 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/05/315/001
RESIST participants receiving Aptivus with ritonavir tended to have an increased risk of bleeding; at 24 weeks the relative risk was 1.98 (95% CI=1.03, 3.80). 
Ispitanici u RESIST studiji koji su dobivali Aptivus s ritonavirom, imali su povećan rizik krvarenja; nakon 24 tjedna, relativni rizik bio je 1,98 (95% CI=1,03; 3,80).
Data suggest that, although ritonavir is a P-gp inhibitor, the net effect of Aptivus, coadministered with low dose ritonavir, at the proposed dose regimen at steady-state, is P-gp induction. 
Dostupni podaci sugeriraju da je, iako je ritonavir P-gp inhibitor, učinak Aptivusa s niskom dozom ritonavira na aktivnost P-gp u stanju dinamičke ravnoteže indukcija.
In an open-label, dose-finding study of tipranavir plus ritonavir (Trial 1182.14), 62 children aged 2 to 12 years received Aptivus oral solution. 
U otvorenom ispitivanju određivanja doze tipranavira s ritonavirom (ispitivanje 1182.14), 28 djece u dobi od 12-18 godina dobivalo je Aptivus kapsule.
You should therefore carefully read the Package Leaflets of ritonavir and your child's other antiretroviral medicines. 
Prema tome, pažljivo pročitajte upute koje se prilažu uz ritonavir i druge antiretrovirusne lijekove koje primjenjuje Vaše dijete.
Depending on your child's liver function they may have to delay or stop Aptivus treatment - if your child is currently taking products containing: - rifampicin (used to treat tuberculosis) - cisapride (used to treat stomach problems) - pimozide or sertindole (used to treat schizophrenia) - quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder) - lurasidone (used to treat schizophrenia) - triazolam or oral midazolam (taken by mouth). 
Ovisno o funkciji jetre Vašeg djeteta, možda će se morati odgoditi ili prekinuti liječenje Aptivusom - ako Vaše dijete trenutno uzima lijekove koji sadrže: - rifampicin (primjenjuje se u liječenju tuberkuloze) - cisaprid (primjenjuje se u liječenju želučanih problema) - pimozid ili sertindol (primjenjuju se u liječenju shizofrenije) - kvetiapin (primjenjuje se u liječenju shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja) - lurasidon (primjenjuje se u liječenju shizofrenije) - triazolam ili oralni midazolam (uzimaju se oralno).
This score (counting the 16 amino acids that have been associated with reduced tipranavir susceptibility and/or reduced viral load response: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D and 84V) was applied to baseline viral protease sequences. 
Ovaj skor (koji broji 16 aminokiselina koje su povezane sa smanjenom osjetljivošću na tipranavir i/ili smanjenim učinkom na virusno opterećenje: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D i 84V) je primijenjen na početne virusne proteazne sekvence.
In the case of tipranavir co-administered with low dose ritonavir, concomitant use with rifampicin is expected to result in sub-optimal levels of tipranavir which may lead to loss of virologic response and possible resistance to tipranavir. 
U slučaju primjene tipranavira, uz nisku dozu ritonavira, očekuje se da istodobna primjena rifampicina rezultira sniženom ekspozicijom tipranaviru, što može dovesti do gubitka virusnog odgovora i moguće otpornosti na tipranavir.
Based on theoretical considerations, tipranavir or ritonavir concentrations might increase upon co-administration with itraconazole or ketoconazole. 
Temeljem teoretskih razmatranja, koncentracije tipranavira ili ritonavira mogu se povećati nakon istodobne primjene s itrakonazolom ili ketokonazolom.
Proportion of patients achieving treatment response at Week 48 (confirmed ≥1 log10 copies/ml decrease in viral load compared to baseline), according to tipranavir baseline mutation score and enfuvirtide use in RESIST patients 
Udio bolesnika s terapijskim odgovorom nakon 48. tjedna (potvrđeno smanjenje virusnog opterećenja ≥1 log10 kopija/ml u usporedbi s početkom), u odnosu na početni „mutacijski skor“ i primjenu enfuvirtida u bolesnika u RESIST
Protease inhibitors 
Inhibitori proteaze
No dosage adjustment necessary. 
Nije potrebno podešavanje doza.
You must take Aptivus in combination with low dose ritonavir and other antiretroviral medicines. 
Morate uzimati Aptivus u kombinaciji s niskom dozom ritonavira uz druge antiretrovirusne lijekove.
Reactivation of herpes simplex and herpes zoster virus infections were observed in the RESIST trials. 
U ispitivanjima RESIST primijećena je reaktivacija infekcija virusom herpes simpleks i herpes zoster.
Analyses of tipranavir resistance in treatment experienced patients Tipranavir with ritonavir response rates in the RESIST studies were assessed by baseline tipranavir genotype and phenotype. 
Analiza otpornosti tipranavira u bolesnika s iskustvom u liječenju Stopa terapijskog odgovora na tipranavir s ritonavirom u RESIST kliničkim ispitivanjima analizirana je u odnosu na početni virusni genotip i fenotip.
No clinically significant change is observed in tipranavir PK parameters. 
Nije primijećena klinički značajna promjena farmakokinetike tipranavira.
3 in the comparator PI/ritonavir (N=727) arm. 
3za kontrolnu skupinu (N=727).
- If you have any further questions, please ask your doctor or your pharmacist. 
- Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Tipranavir, co-administered with low dose ritonavir, exhibits linear pharmacokinetics at steady state. 
Tipranavir s niskom dozom ritonavira u stanju dinamičke ravnoteže pokazuje linearnu farmakokinetiku.
Isolates with baseline fold change of >0 to 3 are considered susceptible; isolates with >3 to 10 fold changes have decreased susceptibility; isolates with >10 fold changes are resistant. 
Izolati koji rastu jednako brzo ili do 3 puta brže u prisustvu tipranavira od divljeg soja virusa smatraju se osjetljivima na tipranavir; izolati s >3 do 10 puta bržim rastom smanjeno su osjetljivi, a izolati koji rastu >10 puta brže su rezistentni.
% with Category C 29.2% Treatment history % with any ARV 96.6% Median # previous 
% sa skupinom C 29,2% Anamneza liječenja % s bilo kojim ARV medijan broja prethodnih NRTI medijan broja prethodnih NNRTI medijan broja prethodnih IP * ADI - AIDS defining illness: stanje koje definira AIDS
- If your child gets any side effects, talk to your child's doctor or pharmacist. 
- Ako Vaše dijete dobije bilo koju nuspojavu, potrebno je obavijestiti djetetovog liječnika ili ljekarnika.
Your child must take Aptivus in combination with low dose ritonavir and other antiretroviral medicines. 
Vaše dijete mora uzimati Aptivus u kombinaciji s niskom dozom ritonavira uz druge antiretrovirusne lijekove.
STATEMENT OF ACTIVE SUBSTANCE(S) Each ml contains 100 mg tipranavir 
NAVOĐENJE DJELATNE(IH) TVARI Jedan ml sadrži 100 mg tipranavira
Switching from Aptivus oral solution to the capsules Aptivus oral solution is not interchangeable with the capsules. 
Aptivus oralna otopina nije zamjenjiva s kapsulama.
If you notice any symptoms of infection (for example fever, enlarged lymph nodes), please inform your child's doctor immediately. 
Ako primijetite simptome infekcije (na primjer vrućica, povećani limfni čvorovi) kod Vašeg djeteta, odmah se obratite djetetovom liječniku.
The oral clearance of tipranavir decreased after the addition of ritonavir which may represent diminished first-pass clearance of the substance at the gastrointestinal tract as well as the liver. 
Klirens tipranavira nakon peroralne primjene smanjio se nakon dodavanja ritonavira, što može biti posljedica smanjenog klirensa „prvog prolaza“ u probavnom sustavu i/ili jetri.
Based on theoretical considerations, bosentan concentrations may increase upon co-administration with tipranavir and low dose ritonavir. 
Temeljem teoretskih razmatranja, koncentracije bosentana se mogu povećati nakon istodobne primjene s tipranavirom uz nisku dozu ritonavira.
Abacavir Cmax ↓ 46% Abacavir AUC ↓ 36% 
Abakavir Cmax ↓ 46% Abakavir AUC ↓ 36%
Concomitant use of rilpivirine with some ritonavir-boosted protease inhibitors has demonstrated an increase in the plasma concentrations of rilpivirine. 
Pokazalo se da istodobna primjena rilpivirina s pojedinim inhibitorima proteaze pojačanima ritonavirom uzrokuje povišenje koncentracije rilpivirina u plazmi.
Ergot derivatives Dihydroergotamine Ergonovine Ergotamine Methylergonovine No interaction study performed 
Derivati ergota Dihidroergotamin Ergonovin
Tell your child's doctor if your child receives medicines such as blood-thinning agents, or if your child is taking vitamin E. Your child's doctor may wish to consider certain precautionary measures in such circumstances. 
Obavijestite djetetovog liječnika ako Vaše dijete uzima lijekove kao što su lijekovi za razrjeđivanje krvi ili ako uzima vitamin E.
NAME OF THE MEDICINAL PRODUCT Aptivus 250 mg soft capsules tipranavir 
NAZIV LIJEKA Aptivus 250 mg meke kapsule tipranavir
The clinical relevance of this reduction in didanosine concentrations has not been established. 
Klinički značaj ovog smanjenja koncentracija didanozina nije utvrđen.
Elimination Administration of 
Eliminacija Primjena
Midazolam Cmax ↔ Midazolam AUC ↑ 5.1 fold 
Midazolam Cmax ↔ Midazolam AUC ↑ 5,1 puta
Clarithromycin Cmax ↔ Clarithromycin AUC ↑ 19% Clarithromycin Cmin ↑ 68% 
Antibiotici Klaritromicin 500 mg BID Klaritromicin Cmax ↔ Klaritromicin AUC ↑ 19% Klaritromicin Cmin ↑ 68%
RESIST participants receiving tipranavir with ritonavir tended to have an increased risk of bleeding; at 24 weeks the relative risk was 1.98 (95% CI=1.03, 3.80). 
Bolesnici u RESIST kliničkom ispitivanju koji su dobivali tipranavir s ritonavirom imali su povećan rizik krvarenja; nakon 24 tjedna relativni rizik iznosio je 1,98 (95% CI=1,03; 3,80).
% with Category C 48.4% Treatment history % with any ARV 96.8% Median # previous 
% sa skupinom C 48,4% Anamneza liječenja % s bilo kojim ARV medijan broja prethodnih NRTI medijan broja prethodnih NNRTI medijan broja prethodnih IP * ADI - AIDS defining illness: stanje koje definira AIDS
Fever - Weight loss - Increased blood levels of the pancreas enzyme amylase - Increases in liver enzyme activity - Hepatitis with liver cell damage due to influence of a toxin 
- povećanja aktivnosti jetrenog enzima - hepatitis s oštećenjem jetrene stanice zbog utjecaja toksina
Among all randomised and treated patients, the median change from baseline in CD4+ cell count at the last measurement up to Week 48 was +23 cells/mm 
Uzimajući u obzir sve randomizirane i liječene bolesnike medijan razlike broja CD4+ stanica između zadnjeg mjerenja (najdulje nakon 48 tjedana) i vrijednosti prije početka liječenja, iznosio je +23 stanice/mm
Common: may affect up to 1 in 10 people - Vomiting - Abdominal pain (tummy pain) - Flatulence (breaking wind more often) - Tiredness - Headache - Mild rashes e.g. with hives or with flat or raised small red spots - Increases in blood lipid (fat) levels - Dyspepsia 
Često: mogu se javiti u do 1 na 10 osoba - povraćanje - abdominalna bol (bol u trbuhu) - nadutost (često puštanje vjetrova) - umor - glavobolja - blagi osipi, npr. uz koprivnjaču, ili ravne ili izbočene male crvene mrlje - povišenje vrijednosti lipida (masnoće) u krvi - dispepsija
The co-administration of tipranavir with vitamin E in the form of TPGS (d-alphatocopherol polyethylene glycol 1000 succinate) from 2,322 IU/m² upwards in rats resulted in a significant increase in effects on coagulation parameters, bleeding events and death. 
Krvarenje primijećeno na štakorima bilo je povezano s produljenim protrombinskim vremenom (PV), aktiviranim parcijalnim tromboplastinskim vremenom (APTV) i smanjenjem nekih faktora ovisnih o vitaminu K. Istodobna primjena tipranavira s vitaminom E u obliku TPGS-a (dalfatokoferol polietilenglikol 1000 sukcinat), u dozi od 2,322 IU/m² naviše, u štakora je rezultirala značajnim povećanjem učinaka na parametre koagulacije, krvarenja i smrt.
The combined use of Aptivus with ritonavir with either omeprazole, esomeprazole or with other proton pump inhibitors is not recommended (see section 4.5). 
Kombinirana primjena Aptivusa s ritonavirom i omeprazola, esomeprazola, ili drugih inhibitora protonske pumpe se ne preporuča (vidjeti dio 4.5).
NAME OF THE MEDICINAL PRODUCT Aptivus 100 mg/ml oral solution tipranavir 
NAZIV LIJEKA Aptivus 100 mg/ml oralna otopina tipranavir
Patients treated with Aptivus and reaching the age of 12 years should be switched to the capsule formulation (see sections 4.4 and 5.1). 
Djeca koja navršavaju 12 godina nastavljaju liječenje Aptivus kapsulama (vidjeti dijelove 4.4 i 5.1).
MARKETING AUTHORISATION NUMBER(S) EU/1/05/315/002 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/05/315/002
Inhibition of CYP 2C9 with firstdose tipranavir /r, then induction of CYP 2C9 with steady-state tipranavir/r 
Inhibicija CYP 2C9 prvom dozom tipranavira/r, zatim indukcija CYP 2C9 tipranavirom/r u stanju ravnoteže
Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase dihydroergotamine, ergonovine, ergotamine and methylergonovine concentrations. 
Temeljem teoretskih razmatranja, očekuje se da tipranavir s niskom dozom ritonavira povećava koncentracije dihidroergotamina, ergonovina, ergotamina i metilergonovina.
Since levels of ethinyl oestradiol are decreased, the co-administration of Aptivus co-administered with low dose ritonavir is not recommended. 
S obzirom da su vrijednosti etinilestradiola snižene, istodobna primjena Aptivusa s niskom dozom ritonavira se ne preporuča.
Your child should continue to take Aptivus for as long as your child's doctor tells him/her. 
Vaše dijete treba nastaviti uzimati Aptivus toliko dugo koliko je propisao djetetov liječnik.
In both studies, a total of 67% patient viruses were resistant and 22% were possibly resistant to the pre-selected comparator PIs. 
Medijan prethodno rabljenih NRTI-a iznosio je 6, NNRTI-a 1 i IP-a 4. U oba ispitivanja, ukupno 67% bolesnika imalo je rezistentne viruse, a 22% moguće rezistentne na prethodno odabrane kontrolne IP.
propylene glycol, mono/diglycerides of caprylic/capric acid, sucralose, ascorbic acid, Butter 
mono/digliceridi kaprilatne/kaprinske kiseline, sukraloza, askorbatna kiselina, okusi maslaca metvice i maslaca karamele.
- If you have any further questions, please ask your child's doctor or pharmacist. 
Ako imate dodatnih pitanja, obratite se djetetovom liječniku ili ljekarniku.
Transient inhibition of P-gp by tipranavir/r, followed by induction of P-gp by tipranavir/r at steadystate 
Prolazna inhibicija P-gp putem tipranavira/r, iza čega slijedi indukcija P-gp putem tipranavira/r u stanju ravnoteže
150 mg/m 2 ritonavir, twice daily. 
500 mg uz ritonavir 200 mg.
In one particular in vitro resistance experiment, an HIV-1 isolate that was 87-fold resistant to tipranavir was selected after 9 months, and contained 10 mutations in the protease: L10F, I13V, V32I, L33F, M36I, K45I, I54V/T, A71V, V82L, I84V as well as a mutation in the gag polyprotein CA/P2 cleavage site. 
U jednom in vitro ispitivanju, HIV-1 izolat, koji je bio 87 puta otporniji na tipranavir (od uobičajeno osjetljivih sojeva) odabran je nakon 9 mjeseci, te je sadržavao 10 mutacija u proteazi: L10F, I13V, V32I, L33F, M36I, K45I, I54V/T, A71V, V82L, I84V kao i mutaciju na gag poliproteinskom CA/P2 mjestu na kojem tipranavir cijepa proteazu.
Concomitant administration of Aptivus, co-administered with low dose ritonavir, and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4). 
Istodobna primjena Aptivusa s niskom dozom ritonavira i ovih glukokortikoida se ne preporučuju, osim ako potencijalni pozitivni učinci liječenja ne nadilaze rizik od sistemskih kortikosteroidnih učinaka (vidjeti dio 4.4).
Through a series of multiple stepwise regression analyses of baseline and on-treatment genotypes from all clinical studies, 16 amino acids have been associated with reduced tipranavir susceptibility and/or reduced 48-week viral load response: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D and 84V. 
Stupnjevita multivarijatna regresijska analiza združenosti genotipova (određenih na početku liječenja ili tijekom liječenja) i terapijskog odgovora ukazala je da je 16 aminokiselina združeno sa smanjenom osjetljivošću na tipranavir i/ili sa manjim odgovorom u smislu broja virusnih replika nakon 48 tjedana liječenja: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D i 84V.
Liver monitoring 
Praćenje funkcije jetre
Digoxin 0.25 mg QD iv 
Digoksin 0,25 mg QD i.v.
NAME OF THE MEDICINAL PRODUCT Aptivus 100 mg/ml oral solution 
NAZIV LIJEKA Aptivus 100 mg/ml oralna otopina
Therefore, the concomitant use of zidovudine or abacavir with Aptivus, co-administered with low dose ritonavir, is not-recommended unless there are no other available NRTIs suitable for patient management (see section 4.5). 
Stoga se istodobna primjena zidovudina ili abakavira s Aptivusom, uz nisku dozu ritonavira, ne preporuča, osim ako su oni jedini NRTI prikladni za zbrinjavanje bolesnika (vidjeti dio 4.5).
The most frequently reported moderate or severe adverse reactions in the 48 week analyses are noted below. 
Najčešće umjerene do teške nuspojave zabilježene tijekom 48 tjedana navedene su u tablici.
Co-administration of etravirine and Aptivus/ritonavir is not recommended. 
Istodobna primjena etravirina i Aptivusa/ritonavira se ne preporučuje.
Due to the marked hepatotoxicity of bosentan and the potential for increasing the liver toxicity associated with Aptivus,co-administered with low dose ritonavir, this combination is not recommended. 
Zbog izražene hepatotoksičnosti bosentana i moguće povećane hepatotoksičnosti Aptivusa s niskom dozom ritonavira, ova kombinacija se ne preporučuje.
These medicines are used to treat anxiety or sleep disorders - ergot derivatives (used to treat headaches) - astemizole or terfenadine (used to treat allergies or hay fever) - simvastatin or lovastatin (used to lower blood cholesterol) - amiodarone, bepridil, flecainide, propafenone or quinidine (used to treat heart disorders) - metoprolol (used to treat heart failure) - alfuzosin and sildenafil (when used to treat a rare blood vessel disorder characterized by increased pressure in the pulmonary artery) - colchicine (when used to treat gout flares in patients with kidney or liver disease). 
Ovi lijekovi se primjenjuju u liječenju anksioznosti ili poremećaja spavanja - derivate ergota (primjenjuju se u liječenju glavobolja) - astemizol ili terfenadin (primjenjuju se u liječenju alergija ili peludne groznice) - simvastatin ili lovastatin (primjenjuju se za snižavanje kolesterola u krvi) - amiodaron, bepridil, flekainid, propafenon, ili kinidin (primjenjuju se u liječenju srčanih poremećaja) - metoprolol (primjenjuje se u liječenju zatajenja srca) - alfuzosin i sildenafil (kada se primjenjuju u liječenju rijetkog poremećaja krvnih žila koji se karakterizira povišenim tlakom u plućnoj arteriji) - kolhicin (kada se primjenjuje u liječenju naglih pogoršanja gihta u bolesnika s bolešću bubrega ili jetre).
Dosing of Aptivus, co-administered with low dose ritonavir, with antacids should be separated by at least a two hours time interval. 
Doziranje Aptivusa s niskom dozom ritonavira i antacida potrebno je odvojiti u minimalnom intervalu od dva sata.
Saquinavir Cmax ↓ 70% Saquinavir AUC ↓ 76% Saquinavir Cmin ↓ 82% 
Sakvinavir Cmax ↓ 70% Sakvinavir AUC ↓ 76% Sakvinavir Cmin ↓ 82%
Alternative or additional contraceptive measures are to be used when oestrogen based oral contraceptives are co-administered with Aptivus co-administered with low dose ritonavir (see section 4.5). 
Potrebno je primjenjivati alternativne ili dodatne kontraceptivne mjere kad se oralni kontraceptivi na bazi estrogena primjenjuju istodobno s Aptivusom i ritonavirom (vidjeti dio 4.5).
You should therefore carefully read the Package Leaflets of ritonavir and your other antiretroviral medicines. 
Prema tome, pažljivo pročitajte upute koje se prilažu uz ritonavir i druge antiretrovirusne lijekove koje primjenjujete.